With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-94-5,4-(Iodomethyl)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.
All starting materials were evaporated with toluene several times and all glassware was dried in oven overnight. A solution of LiHMDS (5.91 ml, 5.91 mmol) in THF (15 ml) was cooled to -78 C. The acetamide Part A(iv) compound(1.0 g, 2.81 mmol) was dissolved in THF (15 ml) and was added dropwise to the LiHMDS solution over 15 min. The reaction was stirred at -78 C. for 15 min and was then warmed to 0 C. for 45 min. The reaction was recooled to -78 C., and distilled DMPU (0.714 ml, 5.91 mmol) was added; the reaction was stirred at -78 C. for about 15 min, then the iodide Part A(v) compound (0.954 g, 4.22 mmol) was added. The reaction was stirred at -78 C. for 1 h and was then slowly warmed to RT and was stirred for 18 h. The reaction was quenched with saturated aqueous NH4Cl (10 mL) and was diluted with EtOAc. The reaction was washed with H2O. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with Brine, dried [MgSO4], filtered, and concentrated in vacuo to give the Part A(vi) compound (1.3 g, quantitative yield) as a yellow oil., 101691-94-5
As the paragraph descriping shows that 101691-94-5 is playing an increasingly important role.
Reference£º
Patent; Bristol-Myers Squibb Company; US2008/21052; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics